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Shearer JA, Coker SJ, Carswell HVO. Detrimental effects of
2-arachidonoylglycerol on whole blood platelet aggregation and on
cerebral blood flow after a focal ischemic insult in rats. Am J Physiol
Heart Circ Physiol 314: H967–H977, 2018. First published January 5,
2018; doi:10.1152/ajpheart.00299.2017.—2-Arachidonoylglycerol
(2-AG) is a major modulator of blood flow and platelet aggregation
and a potential neuroprotectant. The present study investigated, for the
first time, the effects of 2-AG on cerebral blood flow (CBF) in the first
critical hours during middle cerebral artery occlusion (MCAO) and on
platelet aggregation in rats. Adult male Sprague-Dawley rats (n  30)
underwent permanent MCAO under isoflurane anesthesia and were
randomly assigned to receive either 2-AG (6 mg/kg iv), monoacylg-
lycerol lipase inhibitor JZL-184 (10 mg/kg iv), or vehicle (n  6
rats/group) treatment. CBF and cardiovascular responses were mea-
sured, by a blinded investigator, for up to 4 h. In separate experiments,
platelet aggregation by 2-AG (19–300 M) was assessed by whole
blood aggregometry (n  40). 2-AG and JZL-184 significantly in-
creased the severity of the CBF deficit versus vehicle (20.2  8.8%
and 22.7  6.4% vs. 56.4  12.1% of pre-MCAO baseline, respec-
tively, P  0.05) but had no effect on blood pressure or heart rate.
While JZL-184 significantly increased the number of thrombi after
MCAO, this did not reach significance by 2-AG. 2-AG induced
platelet aggregation in rat whole blood in a similar manner to arachi-
donic acid and was significantly reduced by the cyclooxygenase
inhibitors indomethacin and flurbiprofen and the thromboxane recep-
tor antagonist ICI 192,605 (P  0.05). This is the first study showing
that 2-AG increases the severity of the CBF deficit during MCAO, and
further interrogation confirmed 2-AG-induced platelet aggregation in
rats. These findings are important because 2-AG had previously been
shown to exert neuroprotective actions and therefore force us to
reevaluate the circumstances under which 2-AG is beneficial.
NEW & NOTEWORTHY 2-Arachidonoylglycerol (2-AG) has neu-
roprotective properties; however, the present study revealed that 2-AG
increases the severity of the cerebral blood flow deficit during middle
cerebral artery occlusion in rats. Further interrogation showed that
2-AG induces platelet aggregation in rats. These findings force us to
reevaluate the circumstances under which 2-AG is beneficial.
2-arachidonoylglycerol; anti-platelet; cerebral blood flow; cerebral
ischemia; endocannabinoids; stroke; thrombosis
INTRODUCTION
Ischemic stroke is caused by a cerebral blood flow (CBF)
deficit due to vessel occlusion by thrombi or emboli and is a
major cause of mortality and morbidity in older age. With a
paucity of treatments, new information on the role of potential
neuroprotective therapies in ischemic stroke is critical.
The endocannabinoid 2-arachidonoylglycerol (2-AG) in-
duces neuronal survival after brain injury such as traumatic
brain injury (TBI) (48), spinal cord injury (1), and cerebral
ischemic insult (59). 2-AG can act as a full agonist at both
cannabinoid (CB)1 and CB2 receptors and can be rapidly
metabolized in vivo to arachidonic acid and prostaglandin
glycerol ester through enzyme pathways including monoacyl-
glycerol lipase (MAGL) (16) and cyclooxygenase (34). Cyclo-
oxygenase can further metabolize arachidonic acid to PGG2
and PGH2, which in turn may be converted to thromboxane,
prostacyclin, and other prostaglandins, all of which have im-
portant physiological and pathological actions. 2-AG can be
produced by many cells, including endothelial cells and plate-
lets (47). Taken together, endogenous 2-AG carries tremen-
dous implications for disease prevention and progression.
With regard to effects of 2-AG on endothelial cells, 2-AG
has potent vasodilatory effects on the rat middle cerebral artery
(MCA) (24) and acts as a potent vasorelaxant against endothe-
lin-1 (9), which is a potent vasoconstrictor linked to CBF
deficit after ischemic stroke (42). Therefore, 2-AG-induced
vasodilatory effects may alleviate the CBF deficit in ischemic
stroke, which in turn, at least in part, may be responsible for the
neuroprotective effect of 2-AG after MCA occlusion (MCAO)
observed by Wang et al. (59). However, no data are available
concerning the effects of 2-AG on CBF during MCAO.
Regarding the effects of 2-AG on platelets, 2-AG is the
primary endocannabinoid released from activated platelets (41)
with potent proaggregatory effects evident in human platelet
studies (30, 41). Platelet aggregation is known to exacerbate
the severity of the CBF deficit after MCAO; however, despite
evidence that drugs that modify platelet aggregation influence
the outcome in rat models of cerebral ischemia (27), no studies,
to our knowledge, have assessed 2-AG effects on rat platelets.
Therefore, to establish whether 2-AG alleviates or exacer-
bates the severity of the CBF deficit during a cerebral ischemic
insult, we monitored the effect of 2-AG on CBF in the critical
hours after MCAO onset and measured the evolution of pa-
thology. JZL-184 is a potent and selective inhibitor of MAGL
and has been shown to increase endogenous 2-AG in the brain
at 30 min after administration (38). Therefore, we have ad-
dressed our objectives using two strategies, namely, 2-AG
treatment to examine exogenous 2-AG effects and JZL-184
treatment to examine endogenous 2-AG effects. We report that
exogenous and endogenous 2-AG aggravated rather than alle-
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viated the CBF deficit with a subsequent increase in the
evolution of neuronal injury but with no effects on blood
pressure (BP) or heart rate (HR). Interrogation of rat platelet
effects confirmed, for the first time, potent proaggregatory
effects of 2-AG in rats as a potential explanation for the
increased CBF deficit caused by 2-AG.
METHODS
Ethical Statement
All animal experiments were carried out in strict accordance with
the United Kingdom Home Office Guidelines on the Operation of the
Animals (Scientific Procedures) Act of 1986 (Project License Nos.
PPL 60/3775 and 60/3665; Personal License No. PIL 60/11356) and
were performed under ethical approval of University of Strathclyde
Animal Welfare Ethical Review Body. All experimental design, data
analysis, and statistical procedures were performed in accordance with
Animal Research Reporting In Vivo Experiments guidelines for
reporting in vivo experiments (31).
Animals
Male adult Sprague-Dawley rats (stroke study: n  30 and platelet
aggregation study: n  40) were obtained from in-house breeding in
the Biological Procedures Unit, University of Strathclyde. Male ani-
mals, used to exclude potential estrous cycle effects (13), were group
housed under standard conditions at 21°C on a 12:12-h light-dark
cycle with environmental enrichment and ad libitum access to water
and food. All efforts were made to minimize animal suffering, and the
number of animals used, n  6 rats/group for the MCAO study and
n  5–7 rats/group for the platelet study, was based on a priori power
calculations at 80% power and a significance level of 5% (52) and on
previous publications (30, 43, 54). In all experiments, terminal anes-
thesia was induced and maintained by inhalation of isoflurane. Suit-
able depth of anesthesia was assessed by lack of a pedal withdrawal
reflex or corneal reflex, and this depth of anesthesia was maintained
throughout the procedure. Body temperature was monitored continu-
ously with a rectal probe throughout the procedure and maintained
within 36.5–37.5°C using a homeothermic blanket (Harvard Appara-
tus, Kent, Edenbridge, UK).
Permanent Cerebral Ischemia: MCAO Model
Induction of ischemia and measurement of CBF. Anesthesia was
induced in 30 male Sprague-Dawley rats (275–350 g, 8–10 wk old) by
inhalation of isoflurane (5% for induction, 2.25–2.5% for maintenance
via artificial ventilation) in 30% O2-70% N2O at 1 l/min. Physiolog-
ical measurements were monitored wth a pulse oximeter/capnograph
(Medair Life-Sense), and a femoral artery was cannulated for contin-
uous BP monitoring and arterial blood gas measurement before and at
2 and 4 h after occlusion. A venous cannula was inserted for drug
administration. CBF was monitored throughout the procedure using a
laser-Doppler probe (Moor Instruments, Axminster, UK) in the cor-
tical region distal to the MCA at approximately anterior/posterior 3
mm, medial/lateral 4 mm. Readings were recorded beginning 60 min
before the induction of ischemia, at 15-min intervals, and data were
expressed as a percentage of the baseline value. Permanent MCAO
was induced by a 5-0 silicon-coated monofilament (50-3033, Doccol,
Sharon, MA), which was inserted into the left external carotid artery
and advanced along the internal carotid artery to occlude the origin of
the MCA (39). Sham-operated animals underwent MCAO surgery
without insertion of the filament. Animals were maintained for up to
4 h after the onset of MCAO, as neuroprotective effects of 2-AG have
been shown to be mediated by a reduction in the early (1–4 h)
inflammatory response (48) or early endogenous activation of CB
receptors (2). Therefore, the 4 h time point not only allows cardio-
vascular and cerebrovascular responses to be monitored continuously
during MCAO but also allows insights into the effects of 2-AG on the
evolution of neuronal injury and the early microglial response.
A priori exclusion criteria were any rat that exhibited no ischemic
injury on histological examination, showed signs of rupture of the
internal carotid artery, whose laser-Doppler signal was not reduced to
60% of baseline following filament insertion, whose physiological
measurements were outside normal parameters based on Flecknell
(18), or whose oxygen saturation remained below 90%. On the basis
of these criteria, no animals were excluded from the present study.
Treatment protocol. Rats were randomly assigned to five groups
(n  6 rats/group). Work was done in six batches. For each batch, the
names of the five groups were written on one piece of paper each,
crumpled up, and selected out of a beaker by a third party. This
process was repeated for each batch of experiments (or n) with a
different third party each time. In the treatment groups, animals
received either 2-AG (1.2 mg/kg iv bolus over 2 min followed by 4-h
infusion to give a total dose of 6 mg/kg), the MAGL inhibitor JZL-184
(5 mg/kg iv bolus over 5 min followed by 4-h infusion to give a total
dose of 10 mg/kg), or vehicle (PEG-300 iv) starting 15 min before
MCAO. In two groups, rats underwent either MCAO surgery without
treatment or sham surgery. The dose of 2-AG used in this study was
based on Panikashvili et al. (49) and Wang et al. (59), who both used
a single dose of 2-AG at 5 mg/kg (ip bolus) to test effects on neuronal
damage after traumatic brain injury and cerebral ischemia, respec-
tively. Given that the total dose in the present study was not admin-
istered until the end of the occlusion period, an additional 20% of
2-AG and JZL-184 was used.
Termination and histological processing. The experimenter was
blinded to the experimental group to which the animal belonged
(treatment received, stroke, or sham surgery) in all analyses by
recoding of animals by an independent investigator. At the end of each
experiment, animals were euthanized quickly by exsanguination and
decapitation, and the brains were immediately and carefully removed
and frozen in isopentane (42°C) in an attempt to maintain structural
integrity and morphology, avoid autolysis, and avoid pressure on the
unfixed brain, which might have led to morphological artifacts (29,
61). Tissue was stored at 20°C for histological analysis. For the
measurement of injury volume, eight coronal sections (20 m thick)
were taken from distinct neuroanatomic regions within the forebrain
(45) and stained with hematoxylin and eosin. Hematoxylin and eosin-
stained sections were viewed under a light microscope to identify
damaged tissue based on neuronal morphology. Irreversibly damaged
neurons were pyknotic (shrunken or triangular in shape), and the
surrounding neuropil was disrupted and displayed pallor. The injury
was transcribed onto line diagrams of the eight coronal levels for
quantification as previously described (60). The injury boundary was
transcribed based on its relation to anatomic landmarks shown on the
line diagrams. The use of line diagrams prevented quantification of
injury volume from being influenced by tissue edema. Each line
diagram was calibrated before use by confirming that the area of each
coronal section was measured accurately. The injury area in each line
diagram was then quantified using MCID image analysis software.
The injury volume was then calculated from the area under the curve
measured at each of the eight sections against the interaural (IA)
distance, where y intersected x-axes at 12.72 mm IA and 0 mm IA,
respectively, and expressed in cubic millimeters.
Immunofluorescence was performed to identify and quantify mi-
croglia numbers and activation, based on cell morphology, within the
MCA territory at the coronal level of the globus pallidus (2.92 mm IA)
and anterior hippocampus (5.88 mm IA). Microglia were labeled
using a goat polyclonal antibody for ionized Ca2-binding adaptor
molecule 1 (Iba-1; 1:250) and FITC-conjugated rabbit anti-goat sec-
ondary antibody (1:200). Cell nuclei were stained with Vectashield
mounting medium containing DAPI. Thrombi occluding vessels in the
ischemic hemisphere were identified by double labeling with rabbit
antibody for CD41 (integrin-II, 1:250) and mouse antibody for
CD62P (P-selectin, 1:100) and appropriate secondary antibodies
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(FITC-conjugated goat anti-rabbit and TRITC-conjugated goat anti-
mouse antibodies).
Multilayer z-stack images (1 m) were taken at the cortical injury
boundary in the ipsilateral hemisphere and corresponding contralat-
eral regions using a laser scanning confocal microscope (Leica Mi-
crosystems, Milton Keynes, UK) and analyzed using Volocity image-
analysis software (Perkin-Elmer, Cambridge, UK). Activated micro-
glia cells were clearly identified by a skilled observer on the basis of
their morphology, including an enlarged nucleus and shorter, thicker
processes. For each image, the number of microglia present was
quantified and the number of activated microglia was expressed as a
percentage of the total number of microglia present.
Whole Blood Aggregometry
Whole blood aggregometry measures changes in impedance be-
tween two electrodes as platelets adhere without the removal of other
blood constituents that can affect platelet function (21). Forty naïve
adult male Sprague-Dawley rats (300–500 g, aged 10–16 wk) were
anesthetized with 5% isoflurane in 100% O2 at 1 l/min and maintained
with 2–2.75% isolflurane in O2 delivered via a nose cone. A carotid
artery was dissected free of connective tissue and cannulated with
polythene tubing containing heparinized saline (10 U/ml). A 9- to
10-ml volume of arterial blood was withdrawn into heparinized
syringes (20 U/ml of whole blood), diluted 1:1 with 0.9% (wt/vol)
NaCl solution (saline), and stored at room temperature before ag-
gregometry experiments. After blood withdrawal, rats were eutha-
nized with an overdose of 1 ml pentobarbital sodium (Euthatal, 200
mg/ml iv). The diluted blood from each rat was divided into 1-ml
aliquots in plastic cuvettes and warmed to 37°C for 5–10 min before
any aggregating agents were added. Platelet aggregation was mea-
sured using a two-channel Chrono-log 590 whole blood aggregometer
(Labmedics, Stockport, UK), which measured changes in impedence
across electrodes to which platelets and platelet aggregates adhered
(7). After the addition of an aggregatory agent, activated platelets will
adhere and impede conductance of the electrical current between the
electrodes.
Treatment protocol. After an equilibrium period, platelet aggrega-
tion was induced with ADP (0.1–30 M, n  5–6), 2-AG (n  6–13),
and arachidonic acid (n  4–11) at 19–300 M, and responses were
measured at the peak or after 10 min, respectively. In further exper-
iments, aggregation to ADP (1 M), 2-AG (150 M), and arachidonic
acid (75 M) was examined in the absence and presence of the
cyclooxygenase inhibitors indomethacin (3 and 10 M) and flurbi-
profen (10 M) and the thromboxane receptor (TP) antagonist ICI-
192,605 (1 M) added 10 min before the aggregating agent (n 
6–7). Aggregation to 2-AG (150 M) and arachidonic acid (75 M)
was examined in the absence and presence of the fatty acid amide
hydrolase (FAAH) inhibitor URB597 (0.3 M) and MAGL inhibitor
JZL-184 (0.1 M) added alone or in combination with ICI-192,605 (1
M) 10 min before the aggregating agent (n  6). To confirm the role
of MAGL, in an additional set of experiments, JZL-184 (1 M) was
preincubated with blood for 30 min at 37°C before addition of the
aggregating agent (n  5–7). Interactions of 2-AG and arachidonic
acid with 1 M ADP were studied using concentrations that produced
a small aggregation response when added alone (75 M 2-AG and 38
M arachidonic acid), added 1 min before ADP, and the response was
measured at 10 min (n  12). Interactions of 2-AG and arachidonic
acid with ADP were also studied in the presence of cyclooxygenase
inhibitors indomethacin and flurbiprofen and the TP antagonist ICI-
192,605 added 10 min before the first aggregating agent (n  6).
Data and Statistical Analysis
Values are expressed as means  SE of n rats. In MCAO experi-
ments, multiple treatment groups were compared using one-way
ANOVA with Bonferroni correction or a paired t-test for ipsilateral
versus contralateral hemisphere comparisons. Physiological parame-
ters and CBF were recorded at baseline and at 1-h intervals throughout
the experimental period and compared using mixed-model repeated-
measures ANOVA. In the whole blood aggregometry experiments,
aggregation responses in the presence and absence of antagonists or
inhibitors and agonist interactions were compared in aliquots of blood
taken from a single animal. Since some responses were not normally
distributed, as determined by the Shapiro-Wilk test, aggregation
responses in the absence and presence of antagonists or inhibitors
were compared using Friedman tests. For agonist interactions, area
under the curve values were calculated. A probability of P  0.05 was
considered to be statistically significant for all comparisons.
RESULTS
2-AG Increased the CBF Deficit During MCAO With No
Effects on BP or HR
To assess the effects of endogenous and exogenous 2-AG on
local cortical blood flow during MCAO, we monitored CBF by
laser-Doppler flowmetry throughout the experiment. A signif-
icant increase in the severity of the CBF deficit was observed
during MCAO in 2-AG- and JZL-184-treated animals com-
pared with vehicle treatment (Fig. 1). After placement of the
microvascular clip on the left internal carotid artery, blood flow
dropped to ~80% of baseline levels as seen in sham animals [as
previously described (43)]. Perfusion was further decreased
upon insertion of the filament in vehicle-treated and untreated
MCAO groups, to ~45% of baseline flow, where it remained
stable throughout the occlusion period. However, there was a
further significant reduction in CBF to ~20% of baseline levels
in 2-AG- and JZL-184-treated animals versus vehicle treatment
(Fig. 1).
Given that the potential hypotensive effects of 2-AG (for a
review, see Ref. 46) might explain the observed decreased
CBF, we monitored BP and HR throughout the experiment.
However, we found no significant difference in 2-AG- and
JZL-184-treated groups compared with vehicle treatment for
BP or HR (Fig. 2, A and B). In addition, blood gases and body
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Fig. 1. Cortical cerebral blood flow monitored before and during middle
cerebral artery occlusion (means  SE; n  6 for all groups). 2-AG, 2-arachi-
donoylglycerol. P  0.05 for untreated vs. sham groups and *P  0.05 vs.
the vehicle-treated group by mixed-model repeated-measures ANOVA fol-
lowed by multiple comparisons with Bonferroni correction.
H9692-AG POTENTIATES PLATELET AGGREGATION AND CBF DEFICIT
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00299.2017 • www.ajpheart.org
Downloaded from www.physiology.org/journal/ajpheart by ${individualUser.givenNames} ${individualUser.surname} (130.159.082.056) on May 9, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
temperature were tightly controlled, with no significant differ-
ences among the groups (Table 1).
To determine the effect of this reduction in CBF on the
evolution of pathology, we measured early neuronal perikaryal
damage and early microglial activation at the termination of the
experiment. Neuronal damage in the cortex was significantly
increased by ~40% and 50% by 2-AG and JZL-184, respec-
tively, versus vehicle at 4 h after MCAO (Fig. 3, A and C, and
Fig. 4). Increased neuronal damage was not evident in subcor-
tical regions, consistent with the MCA branches supplying the
striatum, being end arteries with no collateral flow, unlike
cortical branches (19). Microglia activation occurs as early as
3–4 h after stroke and is known as a key initial event in the
evolution of damage after stroke (50); however, the efficacy of
2-AG to modulate microglia after stroke has not been studied.
Therefore, the microglial response was assessed in the present
study in brains at 4 h after MCAO. Whereas there was a
significant increase in activation in the ipsilateral hemisphere
versus contralateral, there were no significant effects of 2-AG
or JZL-184 compared with vehicle control (Fig. 3, B and D).
2-AG has previously been shown to induce platelet aggregation
in human blood. As such, we also assessed thrombus formation
in the ischemic hemisphere in the present study to investigate
the potential role of platelet aggregation in mediating the effect
of 2-AG. There was a significant increase in the number of
thrombi in the ipsilateral hemisphere after treatment with
JZL-184 (Fig. 3, E and F). However, this did not reach
significance in 2-AG-treated animals. Collectively, these data
show that exogenous and endogenous 2-AG aggravated the
deficit in CBF with potential pathological consequences, most
likely not mediated via changes in BP or HR.
2-AG Induced Platelet Aggregation Via the Cyclooxygenase
Pathway and Thromboxane A2
To further interrogate mechanisms of 2-AG-induced exac-
erbation of ischemia, proaggregatory effects of 2-AG, previ-
ously shown in human platelets, were studied for the first time
in rats. 2-AG induced platelet aggregation over a concentration
range of 19–300 M with a concentration response curve
comparable to that of arachidonic acid, which were both less
potent than ADP with maximum responses of 12.0  2.1 	
(n  6) and 11.7  0.5 	 (n  11) for 2-AG and arachidonic
acid, respectively, and 18.7  1.5 	 (n  6) for ADP (Fig.
5A). 2-AG (150 M) produced slowly developing platelet
aggregation with the maximum response occurring at the end
of the 10-min observation period (Fig. 5B). A similar aggre-
gation response was observed with arachidonic acid (150 M;
Fig. 5B). In contrast, ADP (1 M) produced a rapid and
reversible response, which peaked at 2 min (Fig. 5B).
2-AG can be metabolized to arachidonic acid with the
further production of proaggregatory mediators. Given the
similar profiles of 2-AG- and arachidonic acid-induced aggre-
gation, the role of arachidonic acid metabolism and production
of proaggregatory mediators in the response to 2-AG were
assessed. The cyclooxygenase inhibitors indomethacin (10
M) and flurbiprofen (10 M) and the TP antagonist ICI-
192,605 (1 M) significantly abolished aggregation induced by
2-AG and arachidonic acid (Fig. 6, A and B). 2-AG-induced
aggregation was also significantly reduced by indomethacin at
3 M (Fig. 6A); however, this concentration did not affect the
response to arachidonic acid (Fig. 6B).
To establish whether MAGL is responsible for the release of
arachidonic acid in 2-AG-induced aggregation, we used a
selective inhibitor of MAGL (JZL-184) as well as FAAH
(URB597). 2-AG- and arachidonic acid-induced aggregation
were not altered by URB597 (0.3 M) or JZL-184 (0.1 M)
(Fig. 7). In addition, attenuation of the 2-AG response by the
TP antagonist ICI-192,605 was not prevented by either
URB597 or JZL-184. To confirm the role of MAGL in rat
platelets, an additional set of experiments was performed in
which a higher concentration of JZL-184 (1 M) was
preincubated with blood for a longer period (30 min at
37°C) before the addition of the aggregating agent. In these
experiments, JZL-184 (1 M) significantly inhibited the
aggregation response to both 2-AG (n  5) and arachidonic
acid (n  7) (Fig. 7).
2-AG is known to interact with other physiological agonists
to enhance aggregation in human platelet-rich plasma (40). We
investigated whether 2-AG/ADP-enhanced aggregation in-
volved arachidonic acid metabolism and production of throm-
boxane A2, as previously described by Baldassarri et al. (3), in
human platelets. Suboptimal concentrations of 2-AG (75 M)
and arachidonic acid (38 M) prolonged and potentiated ADP-
induced aggregation, which was significantly reduced by flur-
biprofen (Fig. 8, A and B) and partially reduced by indometh-
acin at 10 M and ICI-192,605 (Fig. 8A). In contrast, indo-
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Fig. 2. Mean arterial blood pressure (MABP;
A) and heart rate [in beats/min (bpm); B]
monitored before and during middle cerebral
artery occlusion (means  SE; n  6 for all
groups). 2-AG, 2-arachidonoylglycerol. For
MABP, #P  0.05 for the JZL-184-treated
group at 4 h vs. pretreatment (30 min); for
heart rate, #P  0.05 for untreated and vehi-
cle- and JZL-184-treated groups at 4 h vs.
pretreatment (30 min) by mixed-model re-
peated-measures ANOVA followed by multi-
ple comparisons with Bonferroni correction.
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methacin at 3 M significantly increased 2-AG potentiation of
ADP (n  6; Fig. 8A).
DISCUSSION
The major finding in the present study is that 2-AG and
JZL-184 aggravated the severity of the CBF deficit in the first
few pivotal hours during MCAO compared with vehicle, which
led to a different evolution of brain injury.
To our knowledge, this is the first study to investigate the
effects of 2-AG and JZL-184 on CBF during stroke. The first
few hours after permanent MCAO are critical to the develop-
ment of neuronal damage, as the fate of vulnerable, but
potentially viable, tissue surrounding the core is dependent on
residual blood flow through collaterals, and the duration and
severity of ischemia (23). The laser-Doppler probe was placed
above the region perfused by the MCA to measure collateral
blood flow in numerous small vessels supplied by the anterior
communicating and anterior cerebral arteries during the first
4 h. After intraluminal filament insertion, there was a sharp
reduction in CBF, which stabilized at 45% of the baseline
signal in the vehicle-treated and untreated groups, indicating
successful occlusion of the MCA (28), as confirmed by the
presence of neuronal perikaryal damage. There was a further
significant reduction in CBF to ~20% of baseline levels in
2-AG-treated animals versus vehicle treatment. This result was
reproduced by pharmacological enhancement of endogenous
2-AG using JZL-184. In addition, the enhanced CBF deficit
resulted in a significant increase in early neuronal damage in
2-AG- and JZL-184-treated groups versus the vehicle-treated
group. 2-AG and JZL-184 administration were started 15 min
before MCAO, but CBF baseline monitoring was started 60
min before MCAO. Therefore, it can be seen from our data that
there was no influence of either agent before (independently of)
the induction of cerebral ischemia. Taken together, we are
confident that the laser-Doppler flow differences observed in
the present study were indeed due to 2-AG-induced aggrava-
tion of the CBF deficit during MCAO, probably due to reduced
blood flow through collaterals, given the placement of the
laser-Doppler probe. Although the present results are perhaps
surprising, given that 2-AG is a known vasodilator (24), they
provide new information about the role of 2-AG in ischemic
stroke in rats and provide some insights into the published
results from recent clinical studies that have shown that use of
cannabis increased stroke risk (56).
If CBF drops below a certain threshold, tissue damage will
be extended (25). To assess whether the drop in CBF by 2-AG
and JZL-184 affects the evolution of ischemic injury, we
assessed early pathology by identifying pyknotic neurons and
activated microglia histologically postmortem at 4 h post-
MCAO. 2-AG or JZL-184 did not significantly increase mi-
croglial activation as detected by Iba-1 immunostaining. Iba-1
is highly and specifically expressed in monocytic cell lines,
including peripheral macrophages as well as both resting and
activated microglia (27). However, at this early time point,
macrophages are unlikely to have infiltrated the brain paren-
chyma (51). A significant increase in microglial activation in
the ipsilateral hemisphere versus contralateral was observed,
which is consistent with the literature at 4 h after MCAO (50),
indicating that the lack of effect of 2-AG and JZL-184 on
microglial activation is likely to be a valid result and not a typeTa
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II (false negative) error. Whereas microglia become activated
by 4 h after MCAO (50), microglial activation peaks within
2–3 days after MCAO (36). Therefore, further studies at a later
time point postocclusion (24 h) are needed to conclude
whether changes in microglial activation across different ex-
perimental groups exist. On the other hand, 2-AG and JZL-184
increased the development of neuronal perikaryal damage at 4
h after MCAO in the present study. In the present study, we
used fresh-frozen brains for analysis rather than perfused
brains to allow examination of intravascular cellular responses
(platelets and thrombi). This approach has the potential to
generate histological artifacts; therefore, due care was taken to
exsanguinate quickly and remove the brains carefully into
42°C to maintain structural integrity and morphology, avoid
autolysis, avoid pressure on the unfixed brain, and avoid dark
neuron, vacuole, or pigment artifacts (29, 61). Although it is
recognized that early ischemic neuronal changes are histolog-
ically detectable at this early 4 h time point (58), the infarction
is not fully evolved, and the effects of intravenous 2-AG on
ischemic damage needs to be further investigated in future
studies with a longer (24–48 h) survival time point to draw
conclusions on final infarct size. Wang et al. (59) showed that
2-AG induced neuroprotection 24 h after MCAO, implying
that the early increase in injury in the present study was likely
to be an acceleration in evolution of damage rather than a
definitive exacerbation of infarct. Whether a different dose of
M
ic
ro
g
lia
 A
c
ti
v
a
ti
o
n
 (
%
)
0
10
20
30
40
50
60
70
80
90
100
Contralateral hemisphere
Ipsilateral hemisphere
Sham Untreated Vehicle 2-AG JZL184
m
m(
e
m
u l
o
V
yr
u j
nI
3
)
0
20
40
60
80
100
120
140
160
  Subcortical    Cortical
No Treatment
Vehicle
2-AG (6 mg/kg)
JZL 184 (10 mg/kg)
Sham Untreated Vehicle 2-AG JZL184
M
ic
ro
g
lia
 A
c
ti
v
a
ti
o
n
 (
%
)
0
10
20
30
40
50
60
70
80
90
100
Contralateral hemisphere
Ipsilateral hemisphere
er
e
h
p
si
m
e
h
d
er
uj
ni
ni
i
b
m
or
h
T 0
5
10
15
20
25
30
35
Sham 
No Treatment
Vehicle
2-AG (6 mg/kg)
JZL184 (10 mg/kg)
E F
C D
A B
*
*
*
x
*
*
* *
* *
*
Branched
processes
Nucleus
Short, thick
processes
Nucleus
Fig. 3. A: injury volume at 4 h after middle cerebral artery occlusion. B: microglia activation in the cortex at the level of the globlus pallidus (left) and anterior
hippocampus (right) for sham, untreated, vehicle-treated, 2-arachidonoylglycerol (2-AG)-treated, and JZL-184-treated groups. C: representative image of a
hematoxylin and eosin-stained section showing pyknotic shrunken nuclei and pale neuropil with vacuolated cytoplasm in injured tissue (left) vs. large nuclei and
strongly stained, undisrupted cytoplasm in viable tissue (right) (line represents the boundary for injured vs. viable tissue; magnification: 
200). D: representative
confocal images (
400, compressed z-stack) showing an example of resting (left) and activated (right) microglia (scale bar  50 m). E: thrombus formation
in the ischemic hemisphere at 4 h after middle cerebral artery occlusion in sham, untreated, vehicle-treated, 2-AG-treated, and JZL-184-treated groups. F:
representative image of positive staining for CD41 (green) and CD62P (red) showing thrombus formation in the ipsilateral hemisphere (scale bar  100 m).
Values are means  SE; n  6 for all groups for injury, n  4–6 for microglia activation, and n  4–5 for thrombus formation. For injury volume, *P  0.05
vs. the vehicle-treated group; for microglial activation and thrombus formation, *P  0.05 vs. the contralateral hemisphere by paired t-test. xP  0.05 vs. the
sham group by one-way ANOVA followed by multiple comparisons with Bonferroni correction for treatment group comparisons.
H972 2-AG POTENTIATES PLATELET AGGREGATION AND CBF DEFICIT
AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00299.2017 • www.ajpheart.org
Downloaded from www.physiology.org/journal/ajpheart by ${individualUser.givenNames} ${individualUser.surname} (130.159.082.056) on May 9, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
2-AG in the present study may be beneficial despite the
deleterious effects of platelet aggregation is worthy of note;
however, Wang et al. used a single dose similar to that in the
present study. Also worthy of note is that Wang et al. admin-
istered 2-AG by an intraperitoneal bolus rather than intrave-
nous infusion, which was chosen in the present study to
increase the likelihood of exogenous 2-AG reaching the isch-
emic tissue, given its high labile nature in rat plasma (33) and
which may lead to greater platelet effects than an intraperito-
neal bolus.
The mechanisms behind the aggravation of the CBF deficit
during MCAO in the present study are currently unclear.
Parameters such as age, body temperature, BP, HR, and arterial
blood gases were similar in 2-AG- and JZL-184-treated ani-
mals versus the vehicle control and are unlikely to account
for the aggravation of the CBF deficit, implying some other
No Treatment Vehicle 2-AG JZL184
Fig. 4. Representative line diagrams showing
the injury topography observed in untreated,
vehicle-treated, 2-arachidonoylglycerol (2-
AG)-treated, and JZL-184-treated animals.
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underlying cerebrovascular effects of 2-AG. Vasodilatory
action on uncompromised vessels is known to cause redis-
tribution of blood away from compromised regions if auto-
regulation is failing, known as the “steal” phenomenon (20).
However, the steal phenomenon after cerebrovasodilators
still remains controversial (for a review, see Ref. 35), and
whether this explains the increased severity of CBF deficit
by 2-AG after stroke needs further investigation.
After MCAO, the cerebral vasculature becomes prothrom-
botic (10, 14), and platelet aggregation contributes significantly
to MCAO-induced focal cerebral ischemia (11). We showed
that, whereas JZL-184 induced a significant increase in the
number of thrombi in the ipsilateral hemisphere, this signifi-
cant increase was not apparent in 2-AG-treated animals.
Whether this reflects a slightly more potent or local effect of
endogenous 2-AG on thrombi is unclear. 2-AG is a known
proaggregant in human platelets (30) but has not yet been
studied in rat platelets. Therefore, to establish whether proag-
gregation is a plausible mechanism of exacerbation of the
ischemic deficit in our rat model, we confirmed that 2-AG does
indeed induce aggregation of rat platelets. Following this line
of thought, increased neuronal perikaryal damage was not
evident in subcortical regions, consistent with the MCA
branches supplying the striatum, being end arteries with no
collateral flow (37, 53), which would be expected to be more
resistant to the detrimental influence of proaggregatory effects
of 2-AG in permanent MCAO models.
In the present study, 2-AG induced aggregation of rat
platelets at similar concentrations used in human platelet stud-
ies (5, 30, 40), indicating that any species differences in the
stability of 2-AG in plasma between rat and humans (33) is
unlikely to have influenced the response to 2-AG in the present
study. Washed human platelet studies showed a maximal effect
of 2-AG at lower concentrations (10 M) (3, 55), probably due
to lack of other blood components (blood cells, enzymes, or
plasma proteins) that affect the labile nature of 2-AG and/or
platelet function (21).
2-AG and arachidonic acid induced similar aggregation
responses, which were reduced markedly by cyclooxygenase
inhibitors and a TP antagonist, indicating that 2-AG induces
aggregation of rat platelets through metabolism of arachidonic
acid via the cyclooxygenase pathway and production of the
proaggregatory mediator thromboxane A2. This mechanism is
in agreement with work in human whole blood (5, 30) and
washed platelets (3), where 2-AG stimulated the synthesis of
thromboxane A2 in human platelets (3). However, an earlier
study (40) in platelet-rich plasma did not show any sensitivity
of the 2-AG response to cyclooxygenase inhibition. This dis-
crepancy may again be explained by the different methodolo-
gies of platelet analysis (22). In the present study, whole blood
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aggregometry was used to allow platelet function to be evalu-
ated in its physiological milieu, in the presence of red blood
cells and leukocytes, which can modulate platelet aggregation
(17), more akin to the in vivo microenvironment.
Our findings that neither the FAAH inhibitor nor the MAGL
inhibitor altered the aggregation response to 2-AG or arachi-
donic acid are in agreement with some human platelet studies
(3, 40, 55) but not others (5, 30). The reasons for this discrep-
ancy are unclear. We used incubation periods (10 min) of
JZL-184 (0.1 M), similar to those in Straiker et al. (57) and
Chouinard et al. (12), although JZL-184 is known to produce
time-dependent inhibition (maximal at 40 min) (38). However,
in the present study, longer incubations of JZL-184 of 1 M
for 30 min (8, 44) inhibited both 2-AG- and arachidonic
acid-induced platelet aggregation, implying a nonselective role
of JZL-184 at longer incubations.
Taken together, our data suggest that 2-AG is unlikely to
induce platelet aggregation in rat whole blood through metab-
olism by FAAH or MAGL to form arachidonic acid. Rather, it
is possible that 2-AG may induce aggregation via phospho-
lipase A2-mediated release of arachidonic acid or via metabo-
lism of 2-AG to arachidonic acid by other enzymes, such as
cyclooxygenase-2, or plasma esterases (33), which are present
in whole rat blood. In addition, given the reduction in poten-
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tiation by ICI-192,605 and flurbiprofen (Fig. 6A), the interac-
tion between 2-AG and ADP in the present study appears also
to involve metabolism of arachidonic acid and enhanced se-
cretion of thromboxane A2.
In summary, whether 2-AG-induced platelet aggregation is
responsible for the increased CBF deficit in our study needs
further analysis, given that a significant increase in thrombi
was evident only after JZL-184 and not after 2-AG treatment in
the present study, and especially given that preventing platelet
aggregation had beneficial effect in only some (26) but not all
stroke studies (32). However, with millions of people world-
wide taking cannabis, and with endocannabinoids recognized
as potential therapeutic agents in cerebral and myocardial
ischemia (for reviews, see Refs. 4, 6, and 14), it is essential to
identify the mechanisms responsible for the detrimental effects
of 2-AG in stroke uncovered in this study, so that new endo-
cannabinoid-related therapies can be developed that will selec-
tively mediate the beneficial effects but not the detrimental
effects in ischemia. Therefore, further, more indepth studies,
outside the scope of the present work, are required to determine
whether 2-AG, by inducing platelet aggregation, contributes to
the formation of thrombi in the brain vessels that reduce the
blood flow after stroke and whether the effect of 2-AG on CBF
deficit is reversed by treatment with cyclooxygenase inhibitors
or thromboxane receptor antagonists. The present findings
force us to reevaluate the circumstances under which 2-AG is
beneficial and whether systemic 2-AG treatment may represent
an increased risk of thromboembolic-related disorders.
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